Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
Affiliations: Department of Tissue Engineering, Nicolaus Copernicus University, Bydgoszcz, Poland, Department of Histology and Embryology, Nicolaus Copernicus University, Bydgoszcz, Poland, Laboratory of Clinical and Experimental Oncology, Department of Pediatric, Hematology and Oncology Nicolaus Copernicus University, Bydgoszcz, Poland
- Published online on: October 4, 2012 https://doi.org/10.3892/ijo.2012.1653
- Pages: 1943-1949
Copyright: © Kloskowski et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].